Oncology clinical trial design planning based on a multistate model that jointly models progression-free and overall survival endpoints

01/24/2023
by   Alexandra Erdmann, et al.
0

When planning an oncology clinical trial, the usual approach is to assume an exponential distribution for the time-to-event endpoints. Often, besides the gold-standard endpoint overall survival, progression-free survival is considered as a second confirmatory endpoint. We use a survival multistate model to jointly model these two endpoints and find that neither exponential distribution nor proportional hazards will typically hold for both endpoints simultaneously. The multistate model approach allows us to consider the joint distribution of the two endpoints and to derive quantities of interest as the correlation between overall survival and progression-free survival. In this paper, we use the multistate model framework to simulate clinical trials with endpoints OS and PFS and show how design planning questions can be answered using this approach. In addition to the major advantage that we can model non-proportional hazards quite naturally with this approach, the correlation between the two endpoints can be exploited to determine sample size and type-I-error. We consider an oncology trial on non-small-cell lung cancer as a motivating example from which we derive relevant trial design questions. We then illustrate how clinical trial design can be based on simulations from a multistate model. Key applications are co-primary endpoints and group-sequential designs. Simulations for these applications show that the standard simplifying approach often leads to underpowered or overpowered clinical trials. Our approach is quite general and can be extended to more complex trial designs, further endpoints, and other therapeutic areas.

READ FULL TEXT

page 18

page 20

research
10/25/2018

Joint modelling of progression-free and overall survival and computation of correlation measures

In this paper, we derive the joint distribution of progression-free and ...
research
06/28/2023

Confirmatory adaptive group sequential designs for clinical trials with multiple time-to-event outcomes in Markov models

The analysis of multiple time-to-event outcomes in a randomised controll...
research
08/29/2020

Design of phase III trials with long-term survival outcomes based on short-term binary results

Pathologic complete response (pCR) is a common primary endpoint for a ph...
research
05/06/2023

How mature are survival data at the time of an interim analysis in a clinical trial with a survival outcome?

In a clinical trial with a survival outcome, an interim analysis is ofte...
research
08/19/2019

Bayesian models for survival data of clinical trials: Comparison of implementations using R software

Objective: To provide guidance for the use of the main functions availab...
research
10/29/2021

Estimating the Distribution of Ratio of Paired Event Times in Phase II Oncology Trials

With the rapid development of new anti-cancer agents which are cytostati...
research
08/15/2019

A hypothesis test of feasibility for external pilot trials assessing recruitment, follow-up and adherence rates

The power of a large clinical trial can be adversely affected by low rec...

Please sign up or login with your details

Forgot password? Click here to reset